Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 18Lymphoid 15Other solid neoplasm 13Genitourinary 6Gastrointestinal 6Sarcoma 3Dermatologic 3Plasma cell 2Gynecologic 2Classical hematology 2Breast 2Head & Neck 1CNS 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Melanoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 183Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 93Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × alvocidib × Breast × Clear all
NCT00020332 2013-06-17

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00003690 2011-08-03

Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
48 enrolled
BreastDermatologicGenitourinary

Breast Neoplasms, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡